#1 Clinical Trials Search in Europe

Eplontersen

Eplontersen is an investigational drug being studied in clinical trials for the treatment of transthyretin-mediated amyloidosis (ATTR), a rare and serious condition. This article summarizes key information about ongoing clinical trials evaluating eplontersen’s safety and efficacy in patients with different forms of ATTR, including cardiomyopathy and polyneuropathy.

Table of Contents

What is Eplontersen?

Eplontersen is a promising new medication being developed to treat various forms of amyloidosis, a group of rare diseases caused by the buildup of abnormal proteins in organs and tissues. This drug is also known by several other names, including ION-682884, IONIS-TTR-LRx, and AKCEA-TTR-LRx[4]. Eplontersen works by reducing the levels of a protein called transthyretin (TTR) in the blood, which is responsible for the formation of amyloid deposits in certain types of amyloidosis[1].

What Conditions Does Eplontersen Treat?

Eplontersen is being studied for the treatment of several forms of amyloidosis, including:

  • Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM): A condition where amyloid proteins build up in the heart, affecting its function[1].
  • Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (hATTR-PN): A genetic form of amyloidosis that primarily affects the nerves[2].

Both of these conditions can significantly impact a person’s quality of life and life expectancy. Eplontersen aims to slow down or potentially halt the progression of these diseases by targeting the root cause – the abnormal TTR protein.

How is Eplontersen Administered?

Eplontersen is given as a subcutaneous injection, which means it’s injected just under the skin. In most clinical trials, it’s administered once every 4 weeks[1]. This less frequent dosing schedule could be more convenient for patients compared to some other treatments that require weekly injections.

Ongoing Clinical Trials

Several large-scale clinical trials are currently underway to evaluate the effectiveness and safety of Eplontersen:

  • CARDIO-TTRansform: A global study involving about 1400 participants with ATTR-CM[4].
  • NEURO-TTRansform: A study focusing on patients with hATTR-PN[5].
  • Extension studies: Long-term studies to assess the safety and efficacy of Eplontersen over extended periods[1][2].

These trials are being conducted in multiple countries, including a specific study in China (EPIC-ATTR)[3].

How Effective is Eplontersen?

While final results from the ongoing trials are still pending, early data suggests that Eplontersen may be effective in:

  • Reducing serum TTR levels, which is the primary target of the medication[5].
  • Potentially improving or stabilizing symptoms related to nerve function and quality of life in patients with hATTR-PN[5].
  • Possibly reducing cardiovascular events and mortality in patients with ATTR-CM[4].

The ongoing trials are measuring various outcomes, including changes in walking ability (6-minute walk test), quality of life scores, and specific measures of nerve and heart function[4][5].

Safety Profile of Eplontersen

As with any new medication, understanding the safety profile of Eplontersen is crucial. The ongoing clinical trials are closely monitoring for any side effects or adverse events. Some of the key safety aspects being evaluated include:

  • Changes in platelet count, kidney function, and liver enzymes[1].
  • Effects on thyroid function[1].
  • Development of anti-drug antibodies, which could potentially affect the medication’s effectiveness[1].

It’s important to note that patients receiving Eplontersen in clinical trials are also given vitamin A supplements, as the medication can affect vitamin A levels in the body[1].

While the full safety profile is still being established through these trials, the hope is that Eplontersen will provide a well-tolerated treatment option for patients with these challenging forms of amyloidosis.

Aspect Details
Drug Name Eplontersen (also known as ION-682884, IONIS-TTR-LRx, AKCEA-TTR-LRx)
Administration Subcutaneous injection, typically once every 4 weeks
Conditions Studied Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), Hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN)
Key Outcome Measures Serum TTR levels, mNIS+7 score, Norfolk QoL-DN score, cardiovascular events, safety assessments
Trial Phases Phase 1 to Phase 3
Trial Durations Ranging from 24 weeks to 3 years, with some having extension periods
Population Studied Adults with ATTR-CM or hATTR-PN, including specific studies in Japanese and Chinese populations
Primary Objectives Evaluate efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of eplontersen

FAQ

  • What is eplontersen? Eplontersen is an investigational drug being studied for the treatment of transthyretin-mediated amyloidosis (ATTR). It is administered by subcutaneous injection and works by reducing the production of transthyretin (TTR) protein.
  • What conditions is eplontersen being studied for? Eplontersen is being studied for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) and hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN).
  • How is eplontersen administered? Eplontersen is administered by subcutaneous injection, typically once every 4 weeks.
  • What are the main outcomes being measured in eplontersen clinical trials? The main outcomes include changes in TTR protein levels, neurological impairment scores, quality of life measures, cardiovascular events, and safety assessments.
  • How long do the eplontersen clinical trials last? The duration of eplontersen clinical trials varies, but many last between 1-3 years, with some having extension periods for long-term follow-up.

Ongoing Clinical Trials on Eplontersen

  • Long-Term Safety and Efficacy Study of Eplontersen in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    Recruiting

    1 1 1
    Investigated drugs:
    Cyprus France Germany Italy Portugal Spain +1

  • Study on Long-Term Safety of Eplontersen for Adults with Transthyretin-Mediated Amyloid Cardiomyopathy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +6

  • Study on the Effectiveness and Safety of Eplontersen for Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

    Not recruiting

    1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +6

Glossary

  • Transthyretin-mediated amyloidosis (ATTR): A rare disease caused by buildup of abnormal transthyretin protein in various organs and tissues, leading to organ dysfunction.
  • Cardiomyopathy: A group of diseases affecting the heart muscle, often leading to heart enlargement and weakness.
  • Polyneuropathy: A condition affecting multiple nerves throughout the body, often causing weakness, numbness, and pain in the hands and feet.
  • Subcutaneous injection: An injection given into the fatty tissue just beneath the skin.
  • Transthyretin (TTR): A protein produced mainly in the liver that transports thyroid hormones and vitamin A in the blood.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and therapeutic effects.
  • Anti-drug antibodies (ADA): Antibodies produced by the immune system in response to a therapeutic drug, which may affect its efficacy or safety.
  • Modified Neuropathy Impairment Score Plus 7 (mNIS+7): A composite score used to measure neurologic impairment in patients with polyneuropathy.
  • Quality of Life (QoL): A measure of an individual's overall well-being and ability to function in daily life.

References